Dataset Information

Malignant pleural mesothelioma targeted proteomics signature from blood

ABSTRACT: Targeted proteomics based blood biomarkers for malignant pleural mesothelioma cancer

ORGANISM(S): Homo Sapiens

SUBMITTER: Ferdinando Cerciello

PROVIDER: PXD018457 | panorama | Mon Aug 03 00:00:00 BST 2020

REPOSITORIES: PanoramaPublic

ACCESS DATA

Publications

Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma.

Cerciello Ferdinando F Choi Meena M Sinicropi-Yao Sara L SL Lomeo Katie K Amann Joseph M JM Felley-Bosco Emanuela E Stahel Rolf A RA Robinson Bruce W S BWS Creaney Jenette J Pass Harvey I HI Vitek Olga O Carbone David P DP

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20200730 10

<h4>Background</h4>We have verified a mass spectrometry (MS)-based targeted proteomics signature for the detection of malignant pleural mesothelioma (MPM) from the blood.<h4>Methods</h4>A seven-peptide biomarker MPM signature by targeted proteomics in serum was identified in a previous independent study. Here, we have verified the predictive accuracy of a reduced version of that signature, now composed of six-peptide biomarkers. We have applied liquid chromatography-selected reaction monitoring ...[more]

PMID: 32732250

Similar Datasets

Project description:Multiple primary cancers (MPC) refer to the occurrence of two or more independent primary malignant tumors in the same patient, either simultaneously or metachronously. Their clinical diagnosis and differential diagnosis are challenging, treatment strategies are complex, and the incidence has been increasing in recent years. However, there is still a lack of potential biomarkers that can be used for early identification and prognosis assessment, which has become a key bottleneck in current research. This study employed Oxford Nanopore Technologies (ONT) long-read transcriptome sequencing and data-independent acquisition (DIA) proteomics to perform integrated multi-omics analysis of Whole blood samples from patients with only primary lung cancer (OPLC), lung cancer with MPC, and healthy controls (HC), systematically characterizing the molecular features of MPC at both transcript and protein levels. The results showed that MPC patients exhibited significantly increased transcript complexity, with the numbers of differentially expressed genes (DEGs), differentially expressed transcripts (DETs), and differential transcript usage (DTU) events being substantially higher than those in OPLC and HC groups. Multiple genes displayed rich isoform diversity. Functional enrichment analysis indicated that MPC-specific molecules were significantly enriched in immune- and inflammation-related pathways such as NF-κB, NOD-like receptor, Toll-like receptor, and TNF signaling. By integrating gene, transcript, and protein expression profiles, several core molecules (e.g., ATP6AP2, APMAP, CIAO2A, and ITGB2) with consistent expression across multiple regulatory levels were identified, all showing significant and consistent alterations in MPC. This study reveals the molecular characteristics of transcript isoform complexity in the peripheral blood of MPC patients through long-read sequencing combined with proteomics, providing important theoretical insights for understanding the mechanisms of MPC and identifying potential targets.

Dataset Information

Malignant pleural mesothelioma targeted proteomics signature from blood

Publications

Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets